Low-level hepatitis B surface antigen by ECLIA stratifies early relapse risk in patients with interferon-based HBV functional cure - Takeaways - MDSpire

Low-level hepatitis B surface antigen by ECLIA stratifies early relapse risk in patients with interferon-based HBV functional cure

  • By

  • Xiangyong Li

  • Baoer Wu

  • Huaping Xie

  • Hao Hu

  • Ting Liu

  • Xu You

  • Yanhua Bi

  • Yurong Gu

  • July 8, 2026

  • 0 min

Share

  • 1

    This study investigates the use of high-sensitivity ECLIA for detecting low-level HBsAg in patients achieving interferon-induced functional cure.

  • 2

    A total of 292 chronic hepatitis B patients were followed for 48 weeks after achieving functional cure, with 24 patients experiencing relapse.

  • 3

    ECLIA-HBsAg was identified as the sole independent predictor of relapse, with an optimal cutoff of 0.38 COI indicating higher relapse risk.

  • 4

    The mean lead-time gain of ECLIA-HBsAg over ELISA-HBsAg was 28 weeks in functional relapsers, demonstrating its clinical utility.

  • 5

    The findings suggest that ECLIA may redefine the criteria for 'deep functional cure' in chronic hepatitis B management.

Original Source(s)

Low-level hepatitis B surface antigen by ECLIA stratifies early relapse risk in patients with interferon-based HBV functional cure

  • by Xiangyong Li, Baoer Wu, Huaping Xie, Hao Hu, Ting Liu, Xu You, Yanhua Bi, Yurong Gu

  • July 8, 2026

Related Content

EASIX as a moderately effective prognostic marker for mortality in severe acute pancreatitis: a retrospective study

Integrative analysis of GEO data on the microbial community in colorectal cancer tissues and its impact on the tumor immune microenvironment

Association of ultrasound-derived muscle parameters and liver stiffness with low muscle mass in patients with cirrhosis